The Journal of dermatological treatment最新文献

{"title":"Canakinumab for the management of pyoderma gangrenosum: a case series of two patients and literature review.","authors":"Howard Jie Yang, William Spratt, Francis Yi Xing Lai, Senhong Lee","doi":"10.1080/09546634.2025.2495834","DOIUrl":"https://doi.org/10.1080/09546634.2025.2495834","url":null,"abstract":"<p><strong>Aims: </strong>To evaluate the efficacy and adverse events of canakinumab in the treatment of pyoderma gangrenosum (PG).</p><p><strong>Methods: </strong>We report two cases of refractory PG treated with canakinumab after failing multiple therapies.</p><p><strong>Results: </strong>A 44-year-old female achieved complete ulcer resolution after 31 months of canakinumab but experienced recurrent infections, including pneumonia requiring intensive care unit (ICU) admission. A 49-year-old male showed no improvement and suffered recurrent <i>Pseudomonas</i> infections, leading to treatment cessation after nine months.</p><p><strong>Conclusions: </strong>We present a case series of two patients with PG on canakinumab therapy, both of whom experienced significant infections needing hospitalization. Further studies are needed to evaluate the efficacy and complication profile of canakinumab against other biologic therapy options.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2495834"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO study.","authors":"Matthias Augustin, Rudolf E Schopf, Sven R Quist, Nalan Kalyon, Ralph M von Kiedrowski","doi":"10.1080/09546634.2025.2500511","DOIUrl":"10.1080/09546634.2025.2500511","url":null,"abstract":"<p><strong>Aim: </strong>Only limited data is available on the benefit of brodalumab 210 mg, an IL-17 receptor A antagonist, on patient-reported outcomes (PROs) in different psoriasis severity groups under real-world-evidence (RWE) conditions.</p><p><strong>Methods: </strong>LIBERO, a prospective, multicenter, 12- and 52-weeks (W) non-interventional study on brodalumab in adult patients with plaque-type psoriasis assessed its short- and long-term impact on PROs in mild, moderate and severe psoriasis defined by Psoriasis Area Severity Index (PASI).</p><p><strong>Results: </strong>200 (31.3%) patients with severe (PASI ≥ 20), 263 (41.2%) with moderate (PASI = 10-19) and 168 (26.3%) with mild (PASI < 10) psoriasis were analyzed. In all severity groups a rapid and sustained reduction of mean(m) PASI was observed as of W2. 76.7, 84.9 and 82.0% of patients assessed their psoriasis as being clear/almost clear in mild, moderate and severe subgroups and mean Dermatological Life Quality Index improved from 11.2, 14.3 and 17.1 to 3.2, 2.9 and 3.8. 73.7% of patients rated brodalumab as being quite/very beneficial (Patient Benefit Index, PBI) and were quite/very satisfied with the treatment (TSQM-9). Regaining disease control and reducing physical impairment achieved highest PBI-scores.</p><p><strong>Conclusion: </strong>LIBERO confirms the benefit of brodalumab on PROs including rapid and complete clearance of skin lesions, quality of life and individual patient benefits - irrespective of their disease severity.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2500511"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of oral isotretinoin monotherapy compared to combination isotretinoin and topical clascoterone for severe acne vulgaris: a multi-center retrospective study.","authors":"UYeong Choi, Grace Xiong, Dea Metko, Ajith Cy, Smitha Pathayappura, Mohamed Bawazir, Mohannad Abu-Hilal","doi":"10.1080/09546634.2025.2525287","DOIUrl":"10.1080/09546634.2025.2525287","url":null,"abstract":"<p><strong>Introduction: </strong>Severe nodular acne causes significant psychological distress and reduces quality of life. Clascoterone 1% cream, a novel anti-androgen with a favorable safety profile, may enhance the efficacy of oral isotretinoin, the gold-standard therapy for severe acne. This study compared isotretinoin monotherapy with isotretinoin plus topical clascoterone 1% cream.</p><p><strong>Methods: </strong>Since June 2023, patients with severe/nodular acne at university-affiliated dermatology clinics were treated with isotretinoin, alone or combined with clascoterone 1% cream twice daily. In December 2024, records were retrospectively reviewed. The analysis included patients aged ≥12 years with severe/nodular acne who received isotretinoin (0.5-0.8 mg/kg/day) with or without clascoterone 1% cream for ≥24 weeks. Outcomes included facial lesion count, Investigator's Global Assessment (IGA), and facial xerosis at week 24.</p><p><strong>Results: </strong>Eighty-two patients (44 monotherapy; 38 combination therapy) were included. Both groups showed significant reduction in facial lesion count (<i>p < 0.001</i>), but between-group differences were not significant. More patients in the combination group achieved IGA 0/1 (92.1% vs. 72.7%; <i>p < 0.05</i>). Xerosis rates were lower in the combination group (84% vs. 91%) but not statistically significant.</p><p><strong>Conclusion: </strong>Clascoterone 1% cream may enhance isotretinoin efficacy without worsening adverse effects, offering a promising approach for severe/nodular acne. Further studies are needed to confirm long-term benefits.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2525287"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of pemphigus and other neglected skin conditions with PC111, a human anti-Fas Ligand monoclonal antibody: a potential disease modifier.","authors":"Roberta Lotti, Antonino Amato, Brydon Bennett, Tommaso Zanocco-Marani, Alessandra Marconi, Carlo Pincelli","doi":"10.1080/09546634.2025.2526075","DOIUrl":"https://doi.org/10.1080/09546634.2025.2526075","url":null,"abstract":"<p><strong>Background: </strong>Pemphigus vulgaris (PV) is a chronic autoimmune blistering disease with high morbidity and mortality, treated mainly with long-term immunosuppressants. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) is an acute, life-threatening drug reaction with severe skin and mucosal involvement. No approved therapies currently exist for SJS/TEN.</p><p><strong>Aim: </strong>To demonstrate that the soluble form of Fas ligand (sFasL) is a relevant therapeutic target in both PV and SJS/TEN, and to provide evidence that PC111, a fully human monoclonal antibody against sFasL, is effective in both conditions.</p><p><strong>Evidence review: </strong>In PV, autoantibodies (PVIgG) target desmogleins, leading to blistering via signaling cascades. sFasL, released upon PVIgG binding, contributes to this process by promoting desmoglein degradation and acantholysis. In SJS/TEN, elevated sFasL induces keratinocyte apoptosis, contributing to epidermal detachment.</p><p><strong>Findings: </strong>PC111 blocks acantholysis and blister formation in PV through a local, rapid mechanism, downstream of the immune system, thus differentiating from the currently used immunosuppressive treatments. In SJS/TEN, PC111 prevents keratinocyte apoptosis induced by patient serum and improves ocular symptoms in a mouse model. Its fast action suggests potential for early intervention to halt disease progression.</p><p><strong>Conclusions: </strong>PC111 may act as a disease-modifying agent, promoting long-term remission in PV and preventing progression in early-stage SJS/TEN.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2526075"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of sofpironium in treatment of primary hyperhidrosis: a systematic review.","authors":"Ramez M Odat, Abdullah Yousef Aldalati, Bara M Hammadeh, Ayham Mohammad Hussein, Muhammad Idrees, Hamza Marzouk, Sakhr Alshwayyat, Hamdah Hanifa","doi":"10.1080/09546634.2024.2441258","DOIUrl":"10.1080/09546634.2024.2441258","url":null,"abstract":"<p><strong>Background: </strong>Primary axillary hyperhidrosis has limited noninvasive and effective treatment, and we present the use of sofpironium bromide as a promising treatment option. We aimed to assess the efficacy and safety of sofpironium in patients with primary hyperhidrosis.</p><p><strong>Methods: </strong>We systematically searched the databases for Studies that assessed sofpironium bromide in patients with primary axillary hyperhidrosis. Methodological quality was determined using the Cochrane Risk of Bias Assessment tool and Newcastle-Ottowa scale.</p><p><strong>Results: </strong>Five studies were included (752 patients). They used 5% sofpironium, except for one study that used 5%, 10%, and 15% sofpironium. Studies have shown a significant difference in the incidence of patients with an HDSS score of 1 or 2 ranging from 53.9% to 86.7% and reported a greater reduction in the mean change in the DLQI score in the sofpironium group. They also noted a more significant reduction in the total gravimetric weight of sweat in the sofpironium group. A 1.5 point or greater improvement in HDSM-Ax score ranged from 48.2% to 69.1%. Serious adverse events were not observed in the intervention group.</p><p><strong>Conclusion: </strong>Sofpironium gel provides notable improvements in symptom severity, sweat reduction, and quality of life, with mostly mild localized adverse events.Hyperhidrosis is relatively common, affecting 4.8% of the US population and negatively affects physical, social, and psychological well-being.Sofpironium bromide is recently approved by the FDA for the treatment of primary axillary hyperhidrosisSofpironium bromide showed promising results in terms of safety and efficacy for treating hyperhidrosisWe systematically assessed the use of sofpironium gel reported in five studies (752 patients)Sofpironium gel provides notable improvements in symptom severity, sweat reduction and quality of life, with mostly mild localized adverse events.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2441258"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recommendations to optimize gender neutrality in iPLEDGE.","authors":"Nicholas Gessner, Sophia Neman, Klint Peebles, John C Trinidad","doi":"10.1080/09546634.2024.2445773","DOIUrl":"https://doi.org/10.1080/09546634.2024.2445773","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2445773"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of eosinophilic annular erythema with upadacitinib.","authors":"Wanyan Xiang, Siqi Zhang, Qiuju Li, Wenjun Zheng","doi":"10.1080/09546634.2025.2490282","DOIUrl":"https://doi.org/10.1080/09546634.2025.2490282","url":null,"abstract":"<p><strong>Introduction: </strong>Eosinophilic ring erythema (EAE) is a rare eosinophilic dermatosis characterized by ring-shaped or arc-shaped papules and plaques, with eosinophilic infiltration throughout the dermis. Due to the rarity of EAE, established treatment guidelines are currently lacking.</p><p><strong>Case report: </strong>In this report, we present a case of a middle-aged male patient with EAE who exhibited a poor response to systemic immunosuppressants but responded favorably to upadacitinib.</p><p><strong>Conclusion: </strong>This case highlights the potential utility of upadacitinib in managing EAE, particularly in patients unresponsive to conventional therapies.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2490282"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology, genetics and management of vitiligo in the USA: an All of Us investigation.","authors":"Aditya K Gupta, Vasiliki Economopoulos","doi":"10.1080/09546634.2025.2471451","DOIUrl":"10.1080/09546634.2025.2471451","url":null,"abstract":"<p><strong>Background: </strong>Vitiligo is an autoimmune skin depigmentation disorder significantly impacting quality of life. This condition is difficult to treat, with high relapse rates. Additionally, vitiligo associates with other autoimmune conditions, complicating patient management. Improving patient outcomes relies on understanding vitiligo's clinical landscape and genetic risk factors.</p><p><strong>Objectives: </strong>We aimed to understand vitiligo's patient distribution, current management practices, how comorbid autoimmune conditions influence treatment and how genetic risk factors vary in diverse populations.</p><p><strong>Methods: </strong>We conducted a cross-sectional study of the All of Us research program, consisting of surveys, electronic health records and genomic data from 206,173 participants in the USA recruited between the summer of 2017 and 1 July 2022. We determined diagnostic and prescribing rates and elucidated differences in genetic risk within different populations.</p><p><strong>Results: </strong>Oral corticosteroids are most frequently prescribed, followed by other immunosuppressive drugs and topical medications. Comorbid systemic lupus erythematosus impacted treatment choices. Single nucleotide polymorphisms associated with increased risk in patients of European decent were not always associated with increase risk in patients of other ancestry.</p><p><strong>Conclusions: </strong>This work highlights the current treatment landscape for vitiligo in the USA. We demonstrated that comorbid conditions impact treatment choices and genetic risk factors vary between ethnic groups.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2471451"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving the quality of life of patients with inflammatory skin diseases: a multicenter evaluation of a ceramide-containing regimen in patients with atopic dermatitis, psoriasis and xerosis.","authors":"Carlota Abbad-Jaime de Aragon, Emilio Berna-Rico, Leonor Prieto, Mercedes Abarquero-Cerezo, Álvaro Gonzalez-Cantero","doi":"10.1080/09546634.2025.2486702","DOIUrl":"10.1080/09546634.2025.2486702","url":null,"abstract":"<p><strong>Purpose: </strong>Atopic dermatitis (AD), psoriasis and xerosis are characterized by alterations in the skin barrier leading to symptoms that severely impair patients' quality of life (QoL). This multicenter, prospective study evaluated the benefits of a 4-week ceramide-containing regimen on the symptoms and QoL of patients with AD, psoriasis, or xerosis.</p><p><strong>Materials and methods: </strong>Clinical assessments (SCORAD, PASI, VAS), QoL and adherence to the treatment were evaluated at baseline and after 4 weeks.</p><p><strong>Results: </strong>A total of 312 patients (109 AD, 97 psoriasis and 106 xerosis) participated in the study; 59.3% female, mean age 42.4 years, no family history of AD, psoriasis or xerosis in ∼70% of patients. Significant clinical improvements after 4 weeks were reported: 61.2% reduction in SCORAD in AD; 65.5% reduction in PASI in psoriasis; and reductions in VAS for dryness, erythema and other symptoms in xerosis patients. QoL improved in all groups (67.2% AD, 64.7% psoriasis, 77.3% xerosis), with a significant proportion of patients reducing their concomitant treatments. Most patients adhered to the regimen, and no adverse reactions were reported.</p><p><strong>Conclusions: </strong>A ceramide-containing regimen reduced the symptoms commonly associated with AD, psoriasis, and xerosis and improves patients' QoL. Limitations include the lack of control group and limiting conclusions about ceramides' contribution on effectiveness.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2486702"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143805289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bimekizumab as-needed dosing in patients with psoriasis: a case series.","authors":"Carlota Abbad-Jaime De Aragón, Emilio Berna-Rico, Pedro Jaén, Andrew Blauvelt, Álvaro González-Cantero","doi":"10.1080/09546634.2025.2492197","DOIUrl":"https://doi.org/10.1080/09546634.2025.2492197","url":null,"abstract":"<p><strong>Introduction: </strong>Despite significant advances in psoriasis treatment, off-label dosing studies of psoriasis biologic therapies are limited.</p><p><strong>Materials and methods: </strong>In this retrospective case series, medical records from 28 patients with moderate-to-severe psoriasis treated with bimekizumab during 64-week period from May 2023 to October 2024 at the Psoriasis Unit of the Grupo Jaen (Madrid, Spain), were evaluated. Patients were managed with an off-label, as-needed, dosing strategy, with all patients initially receiving two 320 mg doses of bimekizumab at Weeks 0 and 4; subsequent doses were administered only if a given patient dropped below a PASI90 response. Primary outcome was the percentage of patients that achieved and maintained optimal skin control over time, defined as achieving a PASI90 response.</p><p><strong>Results: </strong>Twenty-seven out of the 28 patients achieved a PASI90 response after the first two bimekizumab doses, and all maintained PASI90 responses with as-needed dosing over time. One patient achieved PASI90 after a single dose of bimekizumab, and voluntarily decided not to receive a second dose. No adverse events were observed.</p><p><strong>Conclusions: </strong>Larger prospective studies comparing efficacy and safety of this off-label, as needed, bimekizumab dosing regimen with standard on-label dosing are necessary to corroborate these findings.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2492197"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}